Alogliptin protects Cardiovascular diesase by modurating micro-RNA for diabetis patients - Alogliptin protects Cardiovascular diesase by modurating micro-RNA for diabetis patients

Tokyo Women's Medical University0 个研究点目标入组 60 人开始时间: 2013年1月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients meeting one of the following conditions will be excluded: 1.Under treatment with a thiazolinean, dual or more diabetis drugs, other DPP-4 inhibitors or insulin at the time of study initiation 2. Type 2 and secondary diabetes 3. Severe infectious disease, before or after surgery, and severe trauma 4. Events of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction 5. Moderate renal dysfunction (Serum creatinine (mg/dL): male, 1.4<; female, 1.2<) 6. Severe liver dysfunction (AST: 100 IU/l or higher) 7. Moderate or severer heart failure) (NYHA/New York Heart Association stage III or severer) 8. Under insulin treatment 9. Under treatment with therapeutic drugs not concomitantly administrable with incretin preparations, such as DPP-4 inhibitors, with regard to national health insurance, at the time of study initiation 10. Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 11. Past medical history of hypersensitivity to investigational drugs 12) Judged as ineligible by clinical investigators

发起方

Tokyo Women's Medical University